Author:
Kesselheim Aaron S.,Campbell Eric G.,Schneeweiss Sebastian,Rausch Paula,Lappin Brian M.,Zhou Esther H.,Seeger John D.,Brownstein John S.,Woloshin Steven,Schwartz Lisa M.,Toomey Timothy,Dal Pan Gerald J.,Avorn Jerry
Funder
Study funded by the Center for Drug Evaluation and Research at FDA. Dr. Kesselheim is also supported by a Greenwall Faculty Scholarship in Bioethics
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference58 articles.
1. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Alfred A. Knopf; 2004.
2. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA. 2014;311(4):368–77.
3. Avorn J. In defense of pharmacoepidemiology: embracing the yin and yang of drug research. N Engl J Med. 2007;357(22):2219–21.
4. Assche GV, Van Ranst M, Sciot R, Bénédicte D, et al. Progressive multifocal leukoencephalopathy after natalizumab for Crohn’s disease. N Engl J Med. 2005;353:363–8.
5. Giner L, Nichols CM, Zalsman G, Oquendo MA. Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: an update. Int J Adolesc Med Health. 2005;17(3):211–20.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献